PegBio Co (HKSE:02565) Piotroski F-Score: 2 (As of Aug. 08, 2026) — 33% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02565 PegBio Co Ltd HKSE:02565
11 GF Score
Price HK$6.58
! 4 Warning Signs
View Full Analysis

What is PegBio Co Piotroski F-Score?

PegBio Co HKSE:02565 +23.59% 11 Piotroski F-Score is 2 as of Aug. 08, 2026, which is 33% below its 10-year median of 3.00. GuruFocus rates HKSE:02565 with a GF Score™ of 11/100. The stock has 4 warning signs investors should review. Among 1,324 Biotechnology companies, PegBio Co ranks worse than 73.34% on this metric.

Warning Sign:

Piotroski F-Score of 2 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

PegBio Co has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for PegBio Co's Piotroski F-Score or its related term are showing as below:

HKSE:02565' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 3   Max: 3
Current: 2

During the past 4 years, the highest Piotroski F-Score of PegBio Co was 3. The lowest was 2. And the median was 3.

PegBio Co  (HKSE:02565) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


PegBio Co Piotroski F-Score Related Terms


PegBio Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for PegBio Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PegBio Co Piotroski F-Score Chart

PegBio Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
N/A N/A 3.00 2.00

PegBio Co Semi-Annual Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25
Piotroski F-Score Get a 7-Day Free Trial N/A 0.00 3.00 0.00 2.00

HKSE:02565 vs VRTX, REGN, RVMD: Piotroski F-Score Comparison

For the Biotechnology subindustry, PegBio Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PegBio Co Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PegBio Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where PegBio Co's Piotroski F-Score falls into.


HKSE:02565
11GF Score
PegBio Co Ltd HKSE:02565
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Net Income was HK$-230.18 Mil.
Cash Flow from Operations was HK$-167.81 Mil.
Revenue was HK$0.00 Mil.
Gross Profit was HK$0.00 Mil.
Average Total Assets from the begining of this year (Dec24)
to the end of this year (Dec25) was (233.134 + 661.989) / 2 = HK$447.5615 Mil.
Total Assets at the begining of this year (Dec24) was HK$233.13 Mil.
Long-Term Debt & Capital Lease Obligation was HK$7.28 Mil.
Total Current Assets was HK$614.54 Mil.
Total Current Liabilities was HK$155.83 Mil.
Net Income was HK$-302.32 Mil.

Revenue was HK$0.00 Mil.
Gross Profit was HK$0.00 Mil.
Average Total Assets from the begining of last year (Dec23)
to the end of last year (Dec24) was (402.569 + 233.134) / 2 = HK$317.8515 Mil.
Total Assets at the begining of last year (Dec23) was HK$402.57 Mil.
Long-Term Debt & Capital Lease Obligation was HK$0.24 Mil.
Total Current Assets was HK$203.17 Mil.
Total Current Liabilities was HK$168.34 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

PegBio Co's current Net Income (TTM) was -230.18. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

PegBio Co's current Cash Flow from Operations (TTM) was -167.81. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec24)
=-230.183/233.134
=-0.98734204

ROA (Last Year)=Net Income/Total Assets (Dec23)
=-302.32/402.569
=-0.75097685

PegBio Co's return on assets of this year was -0.98734204. PegBio Co's return on assets of last year was -0.75097685. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

PegBio Co's current Net Income (TTM) was -230.18. PegBio Co's current Cash Flow from Operations (TTM) was -167.81. ==> -167.81 > -230.18 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec24 to Dec25
=7.279/447.5615
=0.01626369

Gearing (Last Year: Dec24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec23 to Dec24
=0.236/317.8515
=0.00074249

PegBio Co's gearing of this year was 0.01626369. PegBio Co's gearing of last year was 0.00074249. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec25)=Total Current Assets/Total Current Liabilities
=614.54/155.827
=3.94373247

Current Ratio (Last Year: Dec24)=Total Current Assets/Total Current Liabilities
=203.172/168.336
=1.20694326

PegBio Co's current ratio of this year was 3.94373247. PegBio Co's current ratio of last year was 1.20694326. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

PegBio Co's number of shares in issue this year was 378.383. PegBio Co's number of shares in issue last year was 279.164. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0/0
=

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

PegBio Co's gross margin of this year was . PegBio Co's gross margin of last year was . ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec24)
=0/233.134
=0

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec23)
=0/402.569
=0

PegBio Co's asset turnover of this year was 0. PegBio Co's asset turnover of last year was 0. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+1+0+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

PegBio Co has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 2 mean?
PegBio Co (HKSE:02565) has a Piotroski F-Score of 2 as of Aug. 08, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on PegBio Co and its competitors. This is 33% below median its historical median of 3.00. Over the past decade, PegBio Co's Piotroski F-Score has ranged from 2.00 to 3.00. According to the industry distribution chart, PegBio Co ranks #971 out of 1324 companies in the Biotechnology industry, placing it in the top 73.3%.
Is PegBio Co's Piotroski F-Score too high?
PegBio Co's current Piotroski F-Score of 2 is 33% below median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 3.00. The Biotechnology industry median Piotroski F-Score is 3.00. PegBio Co's value of 2 is 33.3% below this industry median. Based on the distribution chart, PegBio Co ranks #971 out of 1324 companies in the Biotechnology industry, which is below the industry midpoint. Overall, PegBio Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does PegBio Co's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PegBio Co ranks #971 out of 1324 companies for Piotroski F-Score. This places PegBio Co in the lower half of its industry. The industry median Piotroski F-Score is 3.00. PegBio Co's value of 2 is 33.3% below this benchmark. Historically, PegBio Co's own Piotroski F-Score has ranged from 2.00 to 3.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 3.00, PegBio Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,324 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PegBio Co's current Piotroski F-Score of 2 is 33.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on PegBio Co and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PegBio Co's current Piotroski F-Score is 2, which is 33% below median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PegBio Co stock overvalued right now?
PegBio Co (HKSE:02565) has a current Piotroski F-Score of 2. The current Piotroski F-Score is 2, which is 33% below median its 10-year median of 3.00 and 33.3% below the Biotechnology industry median of 3.00. PegBio Co's overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For PegBio Co (HKSE:02565), the current Piotroski F-Score is 2 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PegBio Co Business Description

Address Haozhang Mansion, Suite 606, Building 1, Gongshu District, Zhejiang, Hangzhou, CHN, 200331
PegBio Co Ltd is engaged in the discovery and development of therapies. The company's main product PB-119, is a self-developed, obtained marketing approval from the National Medical Products Administration (NMPA) and entered commercialization preparation stage, long-acting glucagonlike peptide 1 (GLP-1, a peptide hormone that decreases blood sugar levels) receptor agonist. The Company's product candidates include PB-718, PB-1902, PB-722, PB-2301 and PB-2309.
11GF Score

Get the complete analysis for HKSE:02565

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$6.58
Price